Posted by Michael Wonder on 29 Jun 2020
Successful Eloctaq bid should widen access to the drug in the UK
29 June 2020 - The NHS and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Eloctaq (efmoroctocog alfa), by lifting prior volume restrictions for the drug.
Elocta is licensed by the European Commission in all age groups for treatment and prevention of bleeding in patients with haemophilia A.
It is an extended half-life therapy reimbursed by NHS England and as well, suitable for all age ranges and all severities.
